The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56 + cell dysregulation and is affected by immunomodulatory therapies

Abstract Multiple Sclerosis (MS) is an autoimmune disease treated by therapies targeting peripheral blood cells. We previously identified that expression of two MS-risk genes, the transcription factors EOMES and TBX21 (ET), was low in blood from MS and stable over time. Here we replicated the low ET...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical immunology (Orlando, Fla.) Fla.), 2016-02, Vol.163, p.96-107
Hauptverfasser:	McKay, Fiona C, Gatt, Prudence N, Fewings, Nicole, Parnell, Grant P, Schibeci, Stephen D, Basuki, Monica A.I, Powell, Joseph E, Goldinger, Anita, Fabis-Pedrini, Marzena J, Kermode, Allan G, Burke, Therese, Vucic, Steve, Stewart, Graeme J, Booth, David R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Allergy and Immunology Biomarker Case-Control Studies CD56 Antigen Cell Movement Dimethyl Fumarate - therapeutic use EOMES Epstein-Barr Virus Nuclear Antigens - blood Female Fingolimod Hydrochloride - therapeutic use Gene expression Gene Expression Regulation Genetic Predisposition to Disease Glatiramer Acetate - therapeutic use HLA-DRB1 Chains - genetics Humans Immunologic Factors - therapeutic use Immunosuppressive Agents - therapeutic use Interferon-beta - therapeutic use Longitudinal Studies Male Middle Aged MS risk gene Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - genetics Natalizumab Natalizumab - therapeutic use Polymorphism, Single Nucleotide T-Box Domain Proteins - genetics TBX21 Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!